Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Department of Medicine, Veterans Affairs Boston Healthcare System, Boston, Massachusetts, USA.
Cancer Cytopathol. 2024 Feb;132(2):96-102. doi: 10.1002/cncy.22769. Epub 2023 Oct 16.
Patient-derived organoid models hold promise for advancing clinical cancer research, including diagnosis and personalized and precision medicine approaches, and cytology, in particular, plays a pivotal role in this process. These three-dimensional multicellular structures are heterogeneous, potentially maintain the cancer phenotype, and conserve the genomic, transcriptomic, and epigenomic patterns of the parental tumors. To ensure that only tumor tissue is used for organoid development, cytologic validation is necessary before initiating the process of organoid generation. Here, we explore the technology of tumor organoids and discuss the fundamental application of cytology as a simple and cost-effective approach toward organoid development. We also underscore the potential application of organoid development in drug efficacy studies for lung cancer and head and neck tumors. Additionally, we stress the importance of using fine-needle aspiration to generate tumoroids.
患者来源的类器官模型有望推进癌症临床研究，包括诊断以及个性化和精准医疗方法，细胞学在这个过程中起着关键作用。这些三维多细胞结构具有异质性，可能保持癌症表型，并保留亲本肿瘤的基因组、转录组和表观基因组模式。为了确保仅使用肿瘤组织进行类器官的开发，在开始类器官生成过程之前，需要进行细胞学验证。在这里，我们探讨了肿瘤类器官的技术，并讨论了细胞学作为一种简单且具有成本效益的类器官开发方法的基本应用。我们还强调了类器官开发在肺癌和头颈部肿瘤药物疗效研究中的潜在应用。此外，我们强调了使用细针抽吸来生成类器官的重要性。
